Amicus Therapeutics Stock Today
| FOLD Stock | USD 9.96 0.09 0.91% |
Performance0 of 100
| Odds Of DistressOver 54
|
Amicus Therapeutics is trading at 9.96 as of the 28th of November 2024, a 0.91 percent increase since the beginning of the trading day. The stock's lowest day price was 9.81. Amicus Therapeutics has 54 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. Equity ratings for Amicus Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 29th of October 2024 and ending today, the 28th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 31st of May 2007 | Category Healthcare | Classification Health Care |
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania. Amicus Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 298.81 M outstanding shares of which 21 M shares are currently shorted by private and institutional investors with about 7.28 trading days to cover. More on Amicus Therapeutics
Moving together with Amicus Stock
| 0.67 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
Moving against Amicus Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Amicus Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CEO | Bradley MBA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsAmicus Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Amicus Therapeutics' financial leverage. It provides some insight into what part of Amicus Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Amicus Therapeutics (FOLD) is traded on NASDAQ Exchange in USA. It is located in 47 Hulfish Street, Princeton, NJ, United States, 08542 and employs 500 people. Amicus Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.98 B. Amicus Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 298.81 M outstanding shares of which 21 M shares are currently shorted by private and institutional investors with about 7.28 trading days to cover.
Amicus Therapeutics currently holds about 386.84 M in cash with (69.09 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.38.
Check Amicus Therapeutics Probability Of Bankruptcy
Ownership AllocationThe majority of Amicus Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Amicus Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Amicus Therapeutics. Please pay attention to any change in the institutional holdings of Amicus Therapeutics as this could imply that something significant has changed or is about to change at the company.
Check Amicus Ownership Details
Amicus Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Palo Alto Investors, Llc | 2024-09-30 | 8.1 M | |
| Macquarie Group Ltd | 2024-06-30 | 7.1 M | |
| Geode Capital Management, Llc | 2024-09-30 | 6.6 M | |
| Fiera Capital Corporation | 2024-06-30 | 5.3 M | |
| Pictet Asset Manangement Sa | 2024-06-30 | 4.2 M | |
| American Century Companies Inc | 2024-09-30 | 3.9 M | |
| Citadel Advisors Llc | 2024-09-30 | 3.6 M | |
| Northern Trust Corp | 2024-09-30 | 3.2 M | |
| Massachusetts Financial Services Company | 2024-09-30 | 3.2 M | |
| Vanguard Group Inc | 2024-09-30 | 28.8 M | |
| Perceptive Advisors Llc | 2024-09-30 | 28.1 M |
Amicus Therapeutics Historical Income Statement
Amicus Stock Against Markets
Amicus Therapeutics Corporate Management
| David Clark | Chief Officer | Profile | |
| Patrik Esq | Global Officer | Profile | |
| Patrik Florencio | Global VP | Profile | |
| Simon Harford | Chief Officer | Profile | |
| Ellen Rosenberg | General Counsel and Corporate Secretary | Profile | |
| Ellen JD | Chief Secretary | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Amicus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amicus Therapeutics. If investors know Amicus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amicus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.34) | Revenue Per Share 1.629 | Quarterly Revenue Growth 0.367 | Return On Assets 0.0116 | Return On Equity (0.67) |
The market value of Amicus Therapeutics is measured differently than its book value, which is the value of Amicus that is recorded on the company's balance sheet. Investors also form their own opinion of Amicus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Amicus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amicus Therapeutics' market value can be influenced by many factors that don't directly affect Amicus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amicus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amicus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amicus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.